Announced
Completed
Sartorius Stedim Biotech completed the acquisition of BIA Separations for $422m.
Synopsis
Sartorius Stedim Biotech, a partner of the biopharma industry, completed the acquisition of BIA Separations, a Slovenian biotech company, for $422m. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees," Dr. Joachim Kreuzburg, Chairman of the Board and CEO Sartorius Stedim Biotech.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Seller Team (12)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite